Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease.
de Lau
Lonneke M L
LM
Stricker
Bruno H C
BH
Breteler
Monique M B
MM
D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D003067:Coenzymes / Q000097:blood; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood*; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012307:Risk Factors; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000097:blood
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D003067:Coenzymes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014451:Ubiquinone; D002784:Cholesterol; C024989:coenzyme Q10